American Biosecurity Initiative Responds to Proposed Outbound Investment Rules
America's leadership in biotechnology is essential to our national security, economic competitiveness, and ability to develop new medicines. Protecting sensitive technologies from foreign adversaries is important, and so is preserving America's ability to develop those technologies at home and ensure patients can access promising new treatments.
America Keeps Its Biotech Lead by Building It
You cannot protect American leadership in biotechnology simply by restricting the competition. Trade walls don't synthesize medicines, build manufacturing plants, or discover cures. That is the case Gary Locke, former Washington Governor, Commerce Secretary, and Ambassador to China, and Patrick McHenry, former Chairman of the House Financial Services Committee, make in STAT today. Both serve as senior advisors to the American Biosecurity Initiative.
STATEMENT: The American Biosecurity Initiative Calls for a Durable, Streamlined NIH Research Pipeline
Jennifer A. Crook, executive director of the American Biosecurity Initiative, released the following statement following reports of a potential Executive Order awarding oversight of NIH grants to the Office of Management and Budget.
We Build Our Way to Security: What Washington Heard at the China Biotech Debate
At last week's China Biotech Debate, regulators, investors, and national security veterans kept arriving at that same conclusion from very different starting points. America protects its medicine supply by growing stronger and extending that strength through allies.
GARY LOCKE AND PATRICK McHENRY JOIN ABI AS SENIOR ADVISORS
A former Commerce Secretary and Ambassador to China and a former House Financial Services Chairman join ABI's work to secure America's medicines.
The Surest Protection for American Medicine Is a Stronger America
America's medicine supply is a national security asset, and the surest way to protect it is to build strength at home and extend it through trusted allies. Jennifer Crook made that case in Boston to a room of scientists, investors, and executives who have argued supply chains and China policy for years, and had not yet heard it argued by someone who spent a career inside the intelligence community.
Taking the Argument to Cambridge
ABI's new analysis in Endpoints News says the surest protection is a stronger America. Tomorrow night at MIT, the people who build, fund, and study medicine take up the question.
Making China Weaker Does Not Necessarily Make America Stronger
ABI Executive Director Jennifer Crook, in RealClearDefense, on why the reflex to wall off China's biotech loses a race we should be winning.
Pressure From Abroad, Weakening at Home
America’s medical supply is exposed on two fronts. Most of the current conversation only covers one.
The Frontier Goes to Whoever Shows Up
In biotechnology, the contest is not waiting at the border. It runs at the earliest edge of discovery, across borders, in the licensing deals and partnerships where the next generation of medicines first takes shape. That is the frontier. The question for American policy is whether the United States intends to be present on it.
Where we start
I spent more than twenty-five years in national security, most of it as an intelligence officer at the CIA. For the last decade, I focused on China and technology threats, running enterprise risk assessments on its economic and technological strategy and advising senior decision-makers. I retired from the Agency earlier this year. I founded the American Biosecurity Initiative because I kept seeing the same problem from a new angle, and almost no one was naming it correctly.